Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Kite Pharma, Inc. (KITE)
|
Add to portfolio |
|
|
|
| Price: |
$179.79
| | Metrics |
| OS: |
56.5
|
M
| |
-51
|
% ROE
|
| Market cap: |
$10.2
|
B
| |
-56
|
% ROIC
|
|
Net cash:
|
$781
|
M
| |
$13.81
|
per share
|
|
EV:
|
$9.39
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($336)
|
M
| |
|
|
|
EBIT
|
($356)
|
M
| |
|
|
| EPS |
($6.91)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 |
| Revenues | 22.2 | 17.3 | 0.0 | 0.7 | 0.0 |
| Revenue growth | 28.5% | | -100.0% | 2025.8% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.7 | 0.0 |
| Gross profit | 22.2 | 17.3 | 0.0 | 0.0 | 0.0 |
| Gross margin | 100.0% | 100.0% | | 0.0% | 0.0% |
| Research and development | 197.9 | 76.4 | 23.1 | 5.1 | 1.8 |
| General and administrative | 97.4 | 44.8 | 13.6 | 1.3 | 0.8 |
| EBITA | -269.0 | -101.0 | -36.7 | -6.4 | -2.6 |
| EBITA margin | -1213.3% | -584.9% | | -918.1% | -7838.1% |
| Amortization of intangibles | 4.2 | 3.0 | | | |
| EBIT | -273.2 | -104.0 | -36.7 | -6.4 | -2.6 |
| EBIT margin | -1232.2% | -602.3% | | -918.1% | -7838.1% |
| Pre-tax income | -270.0 | -101.7 | -42.6 | -6.4 | -2.6 |
| Income taxes | -2.9 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 1.1% | 0.0% | 0.0% | | 0.0% |
| Net income | -267.1 | -101.7 | -43.7 | -7.8 | -2.6 |
| Net margin | -1204.6% | -589.0% | | -1114.4% | -7813.8% |
| |
| Diluted EPS | ($5.46) | ($2.33) | ($1.91) | ($1.43) | ($0.48) |
| Shares outstanding (diluted) | 48.9 | 43.6 | 22.8 | 5.5 | 5.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|